Bausch + Lomb Corporation - BLCO STOCK NEWS

Bausch + Lomb (NYSE/TSX: BLCO) has announced the return of enVista® intraocular lenses (IOLs) to market following their voluntary recall. The company has identified that the recall was caused by raw material from a different vendor in certain lots, showing a clear correlation with reported toxic anterior segment syndrome (TASS) cases.

Following a comprehensive investigation conducted with a TASS expert and an advisory group of nearly 30 leading cataract surgeons, Bausch + Lomb has implemented enhanced inspection protocols and stricter standards for monomer preparation by vendors. The company has resumed full production of all enVista IOLs and plans to restore full market supply in the U.S. in the coming weeks.

Market reentry in other countries will be determined through collaboration with local health authorities. Financial impacts of the recall will be discussed during the company's first-quarter earnings call on April 30.

Bausch + Lomb (NYSE/TSX: BLCO) has achieved a significant environmental milestone through its recycling initiatives. The company's ONE by ONE Recycling and Biotrue Eye Care Recycling programs have collectively gathered 103,169,500 units (625,026 pounds) of used contact lenses, eye care, and lens care materials in the United States - equivalent to 600 concert grand pianos.

The ONE by ONE program, launched in November 2016, has collected over 101 million used contact lenses, blister packs, and top foils. The Biotrue Eye Care Recycling program, initiated in April 2021, has accumulated more than 1.3 million eye drop single dose units, lens cases, lens solution caps, and Biotrue-branded eye drop bottles.

This initiative addresses a critical environmental concern, as an estimated 6-10 metric tons of contact lenses end up in wastewater annually in the U.S., potentially affecting aquatic environments and the human food supply. The programs provide a solution for efficiently processing these materials, which are typically challenging to recycle through standard facilities.

Bausch + Lomb (NYSE/TSX: BLCO) has announced a voluntary recall of its enVista platform intraocular lenses (IOLs), including enVista Aspire™, enVista Envy™, and certain enVista® monofocal models. The recall was initiated following reports of toxic anterior segment syndrome (TASS) complications in some patients.

TASS, an inflammatory reaction that typically manifests 12-48 hours post-cataract surgery, has been reported in a small percentage of implanted lenses. Chairman and CEO Brent Saunders emphasized that all reported TASS cases responded well to treatment, with no lens removals required. The company is prioritizing patient safety and is currently communicating with eye care professionals regarding impacted lots and return protocols while working to identify the root cause.

Bausch + Lomb (NYSE/TSX: BLCO) announced it will release its first-quarter 2025 financial results on Wednesday, April 30, 2025. The global eye health company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be available on the company's Investor Relations website section before the call begins.

Bausch + Lomb (NYSE/TSX: BLCO) has launched Arise™, an innovative orthokeratology lens system in the United States. The system features intelligent cloud-based technology that streamlines the lens design process for treating myopia (nearsightedness).

The Arise platform includes the first FDA-approved orthokeratology lens design with toric peripheral curves for overnight myopia treatment. The system efficiently syncs with topographers to create precise lens designs in seconds, eliminating the need for fitting sets. Its advanced algorithms interpret corneal topography images instantly and include an overnight outcome map library for evaluating lens centration and patient progress.

This launch addresses a significant market need, as myopia affects approximately 28% of the global population (2 billion people), with projections showing an increase to 50% (5 billion people) by 2050. The platform is currently available in the United States, United Kingdom, and Europe.

Bausch + Lomb (NYSE/TSX: BLCO) reported Q4 2024 revenue of $1.280 billion, up 9% year-over-year, with an 11% increase on a constant currency basis. The company posted a Q4 GAAP net loss of $3 million.

Full-year 2024 revenue reached $4.791 billion, representing a 16% increase, with growth across all segments. Vision Care revenue grew to $2.739 billion (+8%), Surgical revenue reached $843 million (+10%), and Pharmaceuticals revenue increased to $1.209 billion (+45%).

For 2025, the company projects revenue between $4.950-$5.050 billion, representing 5.5-7.5% constant currency growth, and Adjusted EBITDA of $900-$950 million. The guidance factors in foreign exchange headwinds of -$100M for revenue and -$20M for Adjusted EBITDA.

Bausch + Lomb (NYSE/TSX: BLCO) has announced that its exploration of potential privatization with a third-party buyer has concluded without resulting in a transaction. The company had previously disclosed this possibility in December 2024 following a regulatory request. Full separation from Bausch Health Companies Inc. remains the company's objective.

The eye health company continues to operate independently and execute its business strategies. Notably, BLCO raised its 2024 revenue guidance on October 30 and will report its fourth-quarter and full-year 2024 earnings on February 19, along with providing guidance for fiscal year 2025.

Bausch + Lomb (NYSE/TSX: BLCO) has scheduled the release of its fourth-quarter and full-year 2024 financial results for Wednesday, February 19, 2025. The global eye health company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update.

The company will make all materials available on their Investor Relations website before the call. Participants can join via webcast or through dial-in numbers for North America (+1-888-506-0062) and International (+1-973-528-0011) using access code 785090. A replay will be available until March 5, 2025.

Bausch + Lomb (NYSE/TSX: BLCO), a global leader in eye health, announced the acquisition of Whitecap Biosciences, , enhancing its clinical-stage pipeline. Whitecap is developing two innovative therapies for glaucoma and geographic atrophy (GA). Whitecap Biosciences, founded in 2015, focuses on novel treatments for serious eye diseases, successfully completing Phase 2 trials for WB007 in glaucoma, a potent alpha-2 adrenergic agonist. Further trials are planned for both glaucoma and GA. Glaucoma, a progressive neurodegenerative disease, affects about four million people in the U.S. and is a leading cause of preventable blindness. GA, also known as advanced dry age-related macular degeneration, affects approximately one million people in the U.S. By joining Bausch + Lomb, Whitecap aims to develop its assets into effective treatments to improve visual outcomes.